Artificial intelligence will play an increasingly important role in preventing and treating diseases related to diabetes, ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Zacks highlights strong prospects for COST, CB, and CI, with Costco's steady growth, Chubb's strategic expansion, and Cigna's ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

The company and other insurers have faced backlash from patients who say they were denied necessary care and providers say ...

Getting access to popular weight loss drugs will be simpler and cheaper for some.Health insurer Cigna (CI) announced a new ...

This was the stock's second consecutive day of losses.

On Friday, May 23, UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE: CI) with a price target of $390.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The discussion is almost at a final stage and the company will go to our board, and the board will take a call very soon, ...